All In Biotech

Drug Trial Radar · NCT02769481

Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of Bexagliflozin Versus Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control by Metformin

Last checked: Nov 20, 2026Latest source record: May 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 426 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

426

Actual

Start

Aug 15, 2016

Primary completion

Jun 14, 2019

Study completion Jun 14, 2019

Sponsor

Lead sponsor
TheracosIndustry
Sponsor type
Industry
First posted
May 11, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the effect of bexagliflozin compared to glimepiride as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • BexagliflozinDrug

    20 mg, tablet

  • Placebo for BexagliflozinDrug

    inactive tablet to match active comparator bexagliflozin

  • GlimepirideDrug

    2, 4 or 6 mg, capsule

  • Placebo for GlimepirideDrug

    inactive capsules to match active comparator glimepiride

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in HbA1c at Week 60Time frame: Baseline and Week 60

Locations

45 sites in 4 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Huntington Park, California

  • Research Site

    Los Angeles, California

  • Research Site

    San Carlos, California

  • Research Site

    Hialeah, Florida

  • Research Site

    Miami Lakes, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    West Palm Beach, Florida

  • Research Site

    Calabash, North Carolina

  • Research Site

    Morehead City, North Carolina

  • Research Site

    Magnolia, Texas

  • Research Site

    Aschaffenburg, Germany

  • Research Site

    Essen, Germany

  • Research Site 2

    Essen, Germany

  • Research Site 2

    Hamburg, Germany

  • Research Site

    Hamburg, Germany

  • Research Site

    Heidelberg, Germany

  • Research Site

    Magdeburg, Germany

  • Research Site

    Wangen, Germany

  • Research Site

    Bochnia, Poland

  • Research Site

    Bydgoszcz, Poland

  • Research Site

    Krakow, Poland

  • Research Site 2

    Krakow, Poland

  • Research Site

    Lodz, Poland

  • Research Site 2

    Lublin, Poland

  • Research Site

    Lublin, Poland

  • Research Site

    Olsztyn, Poland

  • Research Site

    Poznan, Poland

  • Research Site

    Puławy, Poland

  • Research Site

    Staszów, Poland

  • Research Site

    Swarzędz, Poland

  • Research Site

    Świdnik, Poland

  • Research Site

    Torun, Poland

  • Research Site

    Warsaw, Poland

  • Research Site

    Zamość, Poland

  • Research Site

    Alicante, Spain

  • Research Site 2

    Barcelona, Spain

  • Research Site

    Barcelona, Spain

  • Research Site 2

    Madrid, Spain

  • Research Site 3

    Madrid, Spain

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.